H. Lim

发表

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.

J. Ahn, D. Lee, Cheryn Song, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

F. Izzo, M. Colombo, Sheng-Nan Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.

J. Heo, T. Sohn, C. Park, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

719PTUMOUR SHRINKAGE AT 6 WEEKS PREDICTS FAVORABLE CLINICAL OUTCOMES IN A PHASE III STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB FOR ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, H. Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients

I. Hwang, Sharrell B Lee, S. Oh, 2011, Cancer Chemotherapy and Pharmacology.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

A. Bass, W. Park, T. Sohn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).

I. Hwang, S. Oh, W. Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

Kwhanmien Kim, H. Kim, J. Y. Choi, 2013, British Journal of Cancer.

Coexisting mycosis fungoides and Hodgkin's disease as a composite lymphoma: a case report.

H. Chung, G. Kim, J. H. Kim, 1991, Yonsei medical journal.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

Sin-Ho Jung, I. Hwang, S. Lim, 2015, British Journal of Cancer.

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP ≥ 400 ng/ml

B. Daniele, F. Piscaglia, D. Sarker, 2021, Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV).

AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).

M. Shah, E. Van Cutsem, A. Ohtsu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2019, Annals of Oncology.

Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron

H. C. Kim, E. Cho, Y. Bang, 2002, The Journal of international medical research.

Alpha-fetoprotein-producing gastric cancer.

S. Noh, S. Rha, J. Min, 1998, Oncology reports.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

D. Chakrabarti, M. Casey, M. Kudo, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

S H Lee, W. Park, Jeeyun Lee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

M. Ahn, S. C. Lee, I. Hwang, 2006, British Journal of Cancer.

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

W. Kang, H. Lim, S. Park, 2017, Journal of Cancer.

Polymorphisms in the IL-13 and IL-4 R genes are associated with the development of renal cell carcinoma

J. Ahn, D. Lee, S. H. Lee, 2022 .

Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.

Jin-Hyuk Choi, Seunghee Kang, M. Chun, 2001, Lung cancer.

Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.

H. S. Kim, H. Joo, Ho Yeong Lim, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer

J. Ahn, J. Kim, Y. Im, 2008, Cancer Chemotherapy and Pharmacology.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

R. Motzer, M. Michaelson, B. Rini, 2014, British Journal of Cancer.

Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Yau, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.

H. Lim, J.O. Park, J. Lee, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

722PMOLECULAR SUBGROUP ANALYSIS OF CLINICAL OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB IN ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, Ho Yeong Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.

W. Kang, H. J. Kim, H. Lim, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.

F. J. Ramos, J. Tabernero, D. Cunningham, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gastric cancer in young patients who underwent curative resection. Comparative study with older patients.

J. Roh, J. Min, H. Chung, 1996, American journal of clinical oncology.

Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast.

J. Roh, S. Rha, J. Min, 1999, International journal of oncology.

Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study.

J. Roh, Jin-Hyuk Choi, Sung Kyu Kim, 1994, Lung cancer.

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.

S. Yoon, H. Lim, J. Park, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.

Y. Koh, S. Rha, Tae Min Kim, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

D. Doval, S. Thongprasert, J. Yi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.

J. Ahn, D. Lee, S. H. Lee, 2012 .

Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.

D. Lim, T. Sohn, J. Bae, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

H. Jang, D. Shin, H. Jeung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY

D. Chakrabarti, M. Kudo, T. Yau, 2014 .

The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.

J. Roh, J. Min, H. Chung, 1992, Yonsei medical journal.

Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma.

J. Tabernero, D. Cunningham, Y. Chao, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.